tq-b3234
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2016 (NCT02996838)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
MAP3K1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- tq-b3234
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05107037 | Phase 1 | Nov 30, 2021 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
| NCT02996838 | Phase 1 | Dec 1, 2016 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd | For profit | 2 | 2 | 1 | 2016 |
1 organizations
Page 1 / 1